PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
Konstantin J. Dedes(University Hospital of Zurich), Jorge S. Reis‐Filho(AstraZeneca (France)), Ana M. Mendes‐Pereira(Institute of Cancer Research), Rachael Natrajan(Institute of Cancer Research), Alan Ashworth(University of California, San Francisco), Alan Mackay(Institute of Cancer Research), Felipe C. Geyer(Memorial Sloan Kettering Cancer Center), Kay Savage(Institute of Cancer Research), Daniel Wetterskog(CRUK Lung Cancer Centre of Excellence), Christopher J. Lord(Institute of Cancer Research), Radost Vatcheva(Institute of Cancer Research), Maryou B. Lambros(Institute of Cancer Research)
Cited by 257
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma
|Cancer Cell|2017|1.3k
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
|New England Journal of Medicine|2012|1k